On social media, Tandem Diabetes Care (Nasdaq:TNDM) said the launch of a new integration for its insulin pump system is near.

Benchmark started Abbott Laboratories with a Buy rating and a $145 price target, calling the diversified healthcare company a steady performer in a volatile global environment.

Abbott Laboratories is set to report Q3 earnings, with EPS expectations of $1.30, reflecting 8.3% YoY growth. Learn more ...

Novo Nordisk’s connected insulin pens will integrate with the Abbott Freestyle Libre system, allowing Freestyle Libre users to see data about their insulin alongside their glucose readings, the ...

A new study published in US Endocrinology found Abbott’s continuous glucose monitoring system, the FreeStyle Libre, demonstrated significant cost savings for diabetic care compared to traditional ...

Abbot⁠t Labor‌atories (NYSE​:ABT) is included among the 13 Most Profitable Dividend Stocks to Buy Right Now. Abbot⁠t ...

Abbott Laboratories recently received Health Canada approval for the Esprit BTK Everolimus Eluting Resorbable Scaffold System ...

Abbott’s ABT diversified business portfolio appears to be well-positioned to drive continued momentum in 2025. The stock carries a Zacks Rank #2 (Buy) currently. Within Abbott’s Established ...

Coca-Cola ( KO 1.04%) and Abbott Laboratories ( ABT -0.51%) are two great examples along those lines. These two companies can offer stability and income to investors, as they belong to the exclusive ...

Abbott Laboratories' said on Monday it had received clearance to market the smallest version of its fastest-growing low-cost diabetes monitoring product in the European Union.